154 related articles for article (PubMed ID: 24788995)
1. The spectrum of tuberculosis infection: new perspectives in the era of biologics.
Delogu G; Goletti D
J Rheumatol Suppl; 2014 May; 91():11-6. PubMed ID: 24788995
[TBL] [Abstract][Full Text] [Related]
2. Tuberculosis reactivation risk in dermatology.
Pescitelli L; Ricceri F; Prignano F
J Rheumatol Suppl; 2014 May; 91():65-70. PubMed ID: 24789002
[TBL] [Abstract][Full Text] [Related]
3. [Biologics and mycobacterial diseases].
Tsuyuguchi K; Matsumoto T
Kekkaku; 2013 Mar; 88(3):337-53. PubMed ID: 23672175
[TBL] [Abstract][Full Text] [Related]
4. Treatment guidelines for latent tuberculosis infection.
;
Kekkaku; 2014 Jan; 89(1):21-37. PubMed ID: 24654427
[TBL] [Abstract][Full Text] [Related]
5. Cellular and humoral immune responses during tuberculosis infection: useful knowledge in the era of biological agents.
Matucci A; Maggi E; Vultaggio A
J Rheumatol Suppl; 2014 May; 91():17-23. PubMed ID: 24788996
[TBL] [Abstract][Full Text] [Related]
6. [Characteristics of a diagnostic method for tuberculosis infection based on whole blood interferon-gamma assay].
Harada N
Kekkaku; 2006 Nov; 81(11):681-6. PubMed ID: 17154047
[TBL] [Abstract][Full Text] [Related]
7. [Evolution of IGRA researches].
Ariga H; Harada N
Kekkaku; 2008 Sep; 83(9):641-52. PubMed ID: 18979999
[TBL] [Abstract][Full Text] [Related]
8. [Development of antituberculous drugs: current status and future prospects].
Tomioka H; Namba K
Kekkaku; 2006 Dec; 81(12):753-74. PubMed ID: 17240921
[TBL] [Abstract][Full Text] [Related]
9. Diagnosis of latent tuberculosis and prevention of reactivation in rheumatic patients receiving biologic therapy: international recommendations.
Iannone F; Cantini F; Lapadula G
J Rheumatol Suppl; 2014 May; 91():41-6. PubMed ID: 24788999
[TBL] [Abstract][Full Text] [Related]
10. Lack of Mycobacterium tuberculosis-specific interleukin-17A-producing CD4+ T cells in active disease.
Perreau M; Rozot V; Welles HC; Belluti-Enders F; Vigano S; Maillard M; Dorta G; Mazza-Stalder J; Bart PA; Roger T; Calandra T; Nicod L; Harari A
Eur J Immunol; 2013 Apr; 43(4):939-48. PubMed ID: 23436562
[TBL] [Abstract][Full Text] [Related]
11. [The clinical application of quantiferon TB-2G: its usefulness and limitations].
Sato S; Nagai H
Kekkaku; 2011 Feb; 86(2):101-12. PubMed ID: 21404654
[TBL] [Abstract][Full Text] [Related]
12. [Lessons learned from tuberculosis outbreak cases].
Kato S; Kuwabara K
Kekkaku; 2014 Feb; 89(2):77-88. PubMed ID: 24716362
[TBL] [Abstract][Full Text] [Related]
13. A multistage-polyepitope vaccine protects against Mycobacterium tuberculosis infection in HLA-DR3 transgenic mice.
Geluk A; van den Eeden SJ; van Meijgaarden KE; Dijkman K; Franken KL; Ottenhoff TH
Vaccine; 2012 Dec; 30(52):7513-21. PubMed ID: 23103299
[TBL] [Abstract][Full Text] [Related]
14. Mycobacterium tuberculosis infection in transplant recipients: early diagnosis and treatment of resistant tuberculosis.
Holty JE; Sista RR
Curr Opin Organ Transplant; 2009 Dec; 14(6):613-8. PubMed ID: 19741533
[TBL] [Abstract][Full Text] [Related]
15. [Prevention of tuberculosis for the immunocompromised host with biological agents and corticosteroid].
Miki M
Nihon Rinsho; 2011 Aug; 69(8):1427-32. PubMed ID: 21838042
[TBL] [Abstract][Full Text] [Related]
16. Tuberculosis vaccines: time to think about the next generation.
Kaufmann SH
Semin Immunol; 2013 Apr; 25(2):172-81. PubMed ID: 23706597
[TBL] [Abstract][Full Text] [Related]
17. Performance of the tuberculin skin test and interferon-γ release assays: an update on the accuracy, cutoff stratification, and new potential immune-based approaches.
Goletti D; Sanduzzi A; Delogu G
J Rheumatol Suppl; 2014 May; 91():24-31. PubMed ID: 24788997
[TBL] [Abstract][Full Text] [Related]
18. Persistent and dormant tubercle bacilli and latent tuberculosis.
Zhang Y
Front Biosci; 2004 May; 9():1136-56. PubMed ID: 14977534
[TBL] [Abstract][Full Text] [Related]
19. Active tuberculosis risk with tumor necrosis factor inhibitors after treating latent tuberculosis.
Kwon M; Sung M; Kwon YJ; Song YG; Lee SW; Park MC; Park YB; Lee SK; Song JJ
J Clin Rheumatol; 2014 Mar; 20(2):68-73. PubMed ID: 24561408
[TBL] [Abstract][Full Text] [Related]
20. Revisiting the natural history of tuberculosis. The inclusion of constant reinfection, host tolerance, and damage-response frameworks leads to a better understanding of latent infection and its evolution towards active disease.
Cardona PJ
Arch Immunol Ther Exp (Warsz); 2010 Feb; 58(1):7-14. PubMed ID: 20049645
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
